Faculty Bibliography

OBJECTIVE:inhibitors for CAS. METHODS:inhibitors as well as symptomatic status. Primary endpoints were perioperative neurologic events (strokes and transient ischemic attacks (TIAs)). Secondary endpoints were mortality and myocardial infarction. RESULTS:inhibitors used revealed that all appeared to be equally effective in reducing the periprocedural neurological event rate. CONCLUSIONS:inhibitors in the periprocedural period, leaving room for significant improvement.

OBJECTIVE:Studies assessing the effect of anticoagulants on endovenous thermal ablation (ETA) are limited to patients on warfarin. As such, the aim of this study was to assess the efficacy and safety of ETA in patients taking direct oral anticoagulants (DOACs). We hypothesized that the outcome of ETA in patients taking DOAC is not superior to the outcome in patients taking DOAC. METHODS:A retrospective review was performed to identify patients undergoing radiofrequency ablation (RFA) and endovenous laser ablation (EVLA) with 1470 nm diode laser fibers for symptomatic great or small saphenous venous reflux from 2018 to 2020. Patients were dichotomized into those receiving therapeutic dose of DOACs peri-procedurally and those not receiving anticoagulants (control). Outcomes of interest included the rates of treated vein closure at 7-days and 9-months, deep venous thrombosis (DVT), endothermal heat-induced thrombosis (EHIT) and bleeding peri-procedurally. RESULTS:There were 87 procedures performed in 69 patients receiving DOACs and 295 procedures in 232 control patients. Patients receiving DOACs were more often older (mean, 65 years vs 55 years; P<.001) and male (70% vs 37%; P<.001), with higher prevalence of venous thromboembolism and more severe CEAP classification (5 or 6), compared to control patients. Those receiving DOAC were more likely to have history of DVT (44% vs 6%; P<.001), PE (13% vs 0%; P<.001) and phlebitis (32% vs 15%; P<.001). Procedurally, RFA was used more frequently in the control group (92% vs 84%; P=.029), with longer segments of vein treated (mean 38 mm vs 35 mm, respectively; P=.028). No major or minor bleeding events nor any EHITs occurred in either group. Two patients (0.7%) in the control group developed DVT whereas no DVT was observed in the those receiving DOAC (P=.441). At 9-months, the treated vein remained ablated after 94.4% of procedures performed in patients receiving DOACs and 98.4% of controls (P=.163). On multivariable analysis, DOAC was not associated with an increased risk of vein recanalization (hazard ratio, 5.76; 95% confidence interval, 0.57-58.64; P=.139). An increased pre-procedural vein diameter and EVLA were associated with an increased risk of recanalization. CONCLUSION/CONCLUSIONS:In this study of patients undergoing ETA for symptomatic saphenous venous reflux, peri-procedural use of DOAC did not adversely affect the efficacy of endovenous ablation to at least 9-months. Furthermore, it did not confer additional risk of bleeding, DVT and EHIT peri-procedurally. As such, the early outcome of ETA in patients not taking DOAC may not be superior to the outcome in patients taking DOAC.

Background: Prior studies have demonstrated that aneurysm sac expansion and failure of sac regression after endovascular aortic repair is associated with higher rates of late mortality and reinterventions. However, the effect of aneurysm sac remodeling on late outcomes after thoracic endovascular aortic repair (TEVAR) is not well-understood.
Method(s): We identified all patients who underwent TEVAR for degenerative aortic aneurysm in the VQI from 2011 to 2018 with 1-year follow-up imaging (+/-6 months) and linkage to Medicare claims data. Sac remodeling was defined as sac expansion (>=5 mm increase), sac stable (<5 mm change), or sac regression (>=5 mm decrease). Mid-term survival, rupture, and reintervention rates were also assessed using Kaplan-Meier estimates. Cox regression was used to assess the impact of sac behavior on midterm outcomes.
Result(s): Among 574 patients, 19% demonstrated sac expansion. Aortic diameter was smallest in patients with sac expansion (expansion 51 mm vs stable/regression 57 mm; P <.001). Sac expansion had the highest rate of any completion endoleak (13% vs 5%; P =.004) and type II completion endoleak (7.8% vs 2.2%; P =.006). An aortic diameter of 65 mm or greater was associated with higher odds of sac regression or stable sac (odds ratio [OR], 2.8; 95% confidence interval [CI], 1.2-6.7; P =.020), while any completion endoleak was associated with higher odds of sac expansion (OR, 3.4; 95% CI, 1.3-8.9; P =.010). Sac expansion trended toward a higher risk of 5-year mortality (21% vs 13%; adjusted hazard ratio, 1.8; 95% CI, 0.9-3.4; P =.079) (Figure) and late rupture (12% vs 4.6%; HR, 3.5; 95% CI, 0.9-13; P =.063). Additionally, sac expansion was associated with higher risk of late reintervention (78% vs 36%; adjusted hazard ratio, 3.0; 95% CI, 18-5.1; P <.001).
Conclusion(s): Sac expansion after TEVAR is associated with increased risk of mid-term rupture and reintervention. Furthermore, completion endoleak is associated with higher odds of sac expansion during follow-up. Further study is warranted to determine if shorter interval follow-up in patients at risk for sac expansion can improve late rupture rates in these patients. [Formula presented]
Copyright

Background: There is a paucity of data regarding outcomes of patients with premature cerebrovascular disease (<=55 years) who undergo carotid endarterectomy (CEA). The objective of this study was to analyze demographics, presentation, perioperative, and later outcomes of younger patients undergoing CEA.
Method(s): The Society for Vascular Surgery Vascular Quality Initiative was queried for CEA cases (2003-2020). Patients were stratified based on age 55 years or less or greater than 55 years. Primary end points were periprocedural stroke, death, myocardial infarction, and composite outcomes. Secondary end points analyzed included ipsilateral restenosis (>=80%) or occlusion, late ipsilateral neurologic events, and reintervention.
Result(s): Of 144,416 patients undergoing CEA, 8264 (5.7%) were aged 55 years or younger. The mean age was 51.3 years (range, 36 to 55 years). Younger patients were more likely to be female (44.5% vs 39.1%) and to be current smokers (58.8% vs 24.4%) (P <.001). They were less likely than older patients to have hypertension (82.2% vs 89.7%), coronary artery disease (25.6% vs 27.9%), and congestive heart failure (7.6% vs 11.2%; P <.001). Younger patients were less likely than older patients to be on aspirin, statins, or beta-blockers, but were more likely to be on P2Y12 inhibitors (P <.001). Younger patients were more likely to present with symptomatic disease (59% vs 47.2%) and were more likely to undergo nonelective CEA (19.3% vs 12.7%; P <.001). Younger patients had similar rates of perioperative stroke/death (1.8% vs 1.9%) and postoperative neurological events (1.7% vs 1.7%), but had lower rates of overall postoperative complications (3.8% vs 4.8%; P <.001). Sixty percent of patients had recorded follow-up (mean, 13 months). During follow-up, younger patients were significantly more likely than older patients to experience complete occlusion or significant (>=80%) restenosis of the operated artery (2.3% vs 1.6%), and were more likely to experience an ipsilateral neurological event (1.4% vs 0.9%) or any neurological event (3.2% vs 2.2%; P <.001).
Conclusion(s): Young patients undergoing CEA are more likely to be female, active smokers, and symptomatic. Although perioperative outcomes are similar, younger patients are more likely to experience carotid occlusion or restenosis as well as subsequent neurological events, during relatively short follow-up. These data suggest that younger CEA patients require more diligent follow-up, and a continued aggressive approach to medical management of atherosclerosis to prevent future events related to the operated artery.
Copyright

Background: Thoracic endovascular aortic repair (TEVAR) is increasingly used to treat aortic dissections and aneurysms. Access-related complications remain a common source of morbidity and mortality following TEVAR. Therefore, this study aims to determine major risk factors predicting postoperative access complications and 3-year survival in patients with access complications.
Method(s): We identified all patients undergoing TEVAR in the Vascular Quality Initiative from July 2010 to August 2021, excluding those converted to open repair. We defined access complication as postoperative occlusion, wound infection, hematoma, or unplanned conversion to open cutdown. The primary outcome was 3-year survival and the secondary outcome was postoperative mortality. Mixed effects logistic regression modelling with physician level clustering was used to identify factors associated with access complications and postoperative mortality. Kaplan-Meier estimates and Cox proportional hazards models were used for analysis of three-year survival.
Result(s): Of 18,172 patients, 1584 (8.7%) had access complications. Bilateral percutaneous access was obtained in 68% of patients, one percutaneous and one open in 14%, and bilateral open access in 13%. Patients with access complications were older (70 +/- 0.6 years vs 66 +/- 0.2 years; P <.01) and female (50% vs 34%; P <.01). Patients with access complications experienced higher postoperative mortality (12% vs 4.6%; P <.01), major adverse cardiac event (17% vs 6.6%; P <.01), reintervention (22% vs 10%; P <.01), and spinal ischemia (7.0% vs 2.1%; P <.01). After adjustment, factors associated with access complication include female sex (odds ratio [OR], 2.2; 95% confidence interval [CI], 1.9-2.6; P <.01) and obesity (OR, 1.2; 95% CI, 1.0-1.4; P =.02). Access complication was independently associated with postoperative mortality (OR, 2.5; 95% CI, 2.0-3.0; P <.01). Bilateral cutdown was associated with lower mortality in male patients (OR, 0.55; 95% CI, 0.34-0.90; P =.02), but not in female patients (OR, 2.1; 95% CI, 1.1-4.3; P =.03). Last, access complications were associated with higher 3 -year mortality (hazard ratio, 1.6; 95% CI, 1.3-1.8; P <.01).
Conclusion(s): Access complications when unexpected are associated with adverse postoperative and three-year outcomes. Female sex is associated with higher rates of access complications, suggesting the need for devices tailored to female anatomy.
Copyright

Background: Preoperative renal function is a predictor of morbidity and mortality after endovascular repair of juxtarenal aortic aneurysms. However, the impact of postoperative renal complication on outcomes after repair are poorly understood. Therefore, our objective was to assess the impact of postoperative renal dysfunction on midterm outcomes following endovascular repair of juxtarenal aortic aneurysms.
Method(s): We identified all endovascular repairs of juxtarenal aortic aneurysms in the Vascular Quality Initiative from 2011 to 2018 with linkage to Medicare claims data. Juxtarenal aortic aneurysm repair was defined as repair with at least one scallop, fenestration, branch, or parallel grafting into a renal vessel. Postoperative renal complication was defined as acute kidney injury (AKI; >=0.5 mg/dL serum creatinine increase) or new renal replacement therapy (RRT). We excluded any patients on preoperative hemodialysis. Kaplan-Meier estimates and Cox regression were used to determine the effect of AKI/RRT on midterm mortality, rupture, and reintervention.
Result(s): Of 931 endovascular repairs, 17% experienced postoperative AKI/RRT. Repairs with postoperative AKI/RRT more often had coverage/occlusion of renal vessels (AKI/RRT: 17% vs stable function: 4.5%; P <.001) or parallel grafting of renal vessels (24% vs 16%; P <.001). Furthermore, repairs with postoperative AKI/RRT had higher rates of postoperative mortality (18% vs 1.2%; P <.001). Postoperative AKI/RRT was independently associated with a higher risk of 5-year mortality (42% vs 16%; adjusted hazard ratio [aHR] 2.4; 95% confidence interval [CI], 1.5-3.8; P <.001) (Figure) and 3-year late rupture (17% vs 5.1%; adjusted hazard ratio, 4.0; 95% CI, 1.8-8.8; P =.001). Meanwhile, postoperative AKI/RRT trended toward a higher risk of 3-year reinterventions (28% vs 20%; adjusted hazard ratio, 1.5; 95% CI, 0.9-2.5; P =.105).
Conclusion(s): Postoperative renal complications adversely impacted late mortality, rupture, and reintervention. Future studies with longer follow-up may likely demonstrate even worse outcomes in this cohort. Our study calls for optimization of preoperative renal status and the use of protective adjuncts to reduce the risk of postoperative renal complications and its negative long-term sequala. [Formula presented]
Copyright

Background: Endovascular aortic aneurysm repair (EVAR) for aortoiliac aneurysms may require sacrifice of the hypogastric artery (HA) or use of iliac branch devices (IBD) to salvage antegrade flow through the HA.
Method(s): We identified all patients who underwent elective EVAR for aortoiliac aneurysms in the Society for Vascular Surgery-Vascular Quality Initiative (2014-2021). Patients were categorized as unilateral/bilateral IBD, bilateral HA sacrifice, or mixed (unilateral HA sacrifice or one-sided IBD/one-sided HA sacrifice). HA sacrifice was defined as coil embolization, Amplatzer plug, or coverage of HA. We compared postoperative outcomes, aneurysm sac remodeling, and late survival across the three groups. Logistic regression and Cox regression were used to identify independent effect of HA patency on outcomes of interest.
Result(s): Among 2822 patients undergoing EVAR for aortoiliac aneurysms, after EVAR 29% had bilateral HA patency, 64% had mixed repair, 7% had bilateral HA sacrifice. Patients with bilateral HA patency had smaller aortic diameter (bilateral patency 5.0 cm vs mixed repair 5.2 cm vs bilateral sacrifice 5.2 cm; P <.001) and fewer concomitant iliac artery and HA aneurysms (14% vs 16% vs 23%; P <.001). Unilateral and bilateral HA patency was associated with lower odds of major adverse cardiac events and postoperative renal complications (Table). There was no association between HA patency and postoperative mortality (0.6% vs 1.2% vs 1.1%; P =.35), leg ischemia (1.0% vs 1.0% vs 1.1%; P =.98), or mesenteric ischemia (0.2% vs 0.3% vs 0.5%; P =.80). There were no differences in 1-year sac shrinkage (>=5 mm decrease) (39% vs 40% vs 45%; P =.580) or 5-year survival (92% vs 94% vs 89%; P =.435).
Conclusion(s): In patients with aortoiliac aneurysms, bilateral HA patency was associated with lower postoperative major adverse cardiac events and renal complications. Salvage of the HA is important for quality of life and functional capacity, but future studies with larger sample sizes are needed. [Formula presented]
Copyright

Background: Interventions for carotid occlusions are infrequently undertaken and the outcomes are poorly defined. We sought to study patients undergoing urgent carotid revascularization for symptomatic occlusions.
Method(s): The Society for Vascular Surgery Vascular Quality Initiative was queried from 2003 to 2020 to identify patients with carotid occlusions undergoing carotid endarterectomy. Only symptomatic patients undergoing urgent interventions, defined within 24 hours of presentation, were included in this analysis. This cohort was compared to patients undergoing urgent intervention for severe stenosis (>=80%). Patients were identified based on computed tomography and magnetic resonance imaging, only. The primary end points were perioperative stroke, death, myocardial infarction (MI), and composite outcomes.
Result(s): A total of 390 patients were identified who underwent urgent carotid endarterectomy for symptomatic occlusions. The mean age was 67.4 +/- 10.2 years with a range from 39 to 90 years. The cohort was predominantly male (60%), and had significant risk factors for cerebrovascular disease, including hypertension (87.4%), diabetes (34.4%), coronary artery disease (21.6%), current smoking (38.7%), chronic obstructive pulmonary disease (21.6%), and congestive heart failure (10.3%). Medications included statin therapy (78.6%), P2Y12 inhibitors (32.0%), aspirin (77.9%) and renin-angiotensin inhibitor use (43.7%). The perioperative rate of neurologic events was 4.9%%, associated mortality was 2.8% and rate of MI was 1.0%. The composite end point of stroke/death/MI was 7.7%. When compared to patients undergoing urgent endarterectomy for severe stenosis (>=80%), the two cohorts were well matched with regards to risk factors, but the severe stenosis cohort appeared to be better medically managed based on reported medications. In the severe stenosis group, the perioperative rate of neurologic events was 3.3%, associated mortality was 0.9% and rate of MI was 1.2%. The perioperative outcomes were significantly worse for the carotid occlusion cohort, primarily driven by the perioperative mortality, which was nearly threefold, 2.8% versus 0.9% (P <.001). The composite end point of stroke/death/MI was also significantly worse in the occlusion cohort (7.7% vs 4.9%; P =.014).
Conclusion(s): Revascularization for symptomatic carotid occlusion constitutes approximately 2% of carotid interventions captured in the Vascular Quality Initiative, affirming the rarity of this undertaking. These patients have acceptable rates of perioperative neurologic events but are at an elevated risk of overall perioperative adverse events, primarily driven by a significantly higher mortality. While intervention for a symptomatic carotid occlusion may be performed with acceptable rate of perioperative complications, judicious patient selection is warranted in this high-risk cohort.
Copyright

OBJECTIVE:Current guidelines recommend dual antiplatelet therapy (DAPT) in patients undergoing carotid artery stenting. The most common DAPT regimen is aspirin and clopidogrel, a P2Y12 receptor antagonist; however, the prevalence of clopidogrel resistance (CR) in patients undergoing percutaneous coronary interventions may exceed 60%. Few studies have investigated the prevalence and impact of CR in patients undergoing extracranial carotid artery stenting, particularly transcarotid artery revascularization (TCAR). METHODS:Consecutive high-risk patients ≥ 18 years who underwent TCAR for high grade (≥70%) and/or symptomatic (≥50%) carotid stenosis with preoperative P2Y12 testing between August 2019 and December 2021 were identified across five institutions. Preoperative platelet reactivity was measured with the VerifyNow P2Y12 Reaction Unit (PRU) Test (Instrumentation Laboratory, Bedford, MA), with CR defined as PRU ≥ 194 and hyper-response as PRU <70. Patients without preoperative P2Y12 testing within 30 days prior to TCAR or those on a non-clopidogrel P2Y12 inhibitor preoperatively were excluded. The primary outcome of interest was prevalence of CR. Secondary outcomes of interest included the incidence of ischemic and hemorrhagic complications. RESULTS:= 1) between clopidogrel phenotypes. Three (3.3%) patients, one CR (PRU 240) and two responders (PRU 119 and PRU 189), experienced postoperative access site hematomas that required no subsequent intervention. No other index hospitalization hemorrhagic complications occurred. CONCLUSIONS:Using preoperative P2Y12 testing with a threshold PRU ≥ 194 to define CR, we identified a high prevalence of CR in patients undergoing TCAR similar to that in the pre-existing coronary literature. We found no significant differences in postoperative ischemic or hemorrhagic complications by clopidogrel response phenotype, although complication rates in the overall study cohort were low. CR may be a spectrum from responder to partial responder to complete non-responder, and this may account for the differences in our CR cohort compared to the ROADSTER 2 protocol deviation cohort. Further investigation is warranted to determine if a quantitative assessment of CR is sufficient to identify patients at risk of developing secondary cerebrovascular ischemic events in this patient population.

Objectives: Beta-blockers are first-line anti-impulse therapy for patients presenting with type B aortic dissection (TBAD); however, little is understood about their impact after aortic repair. The aim of this study was to evaluate the role of postoperative beta-blocker use on the outcomes of thoracic endovascular aortic repair (TEVAR) for TBAD.
Method(s): The Vascular Quality Initiative database was queried for all patients undergoing TEVAR for TBAD from 2012 to 2020. Aortic-related reintervention, all-cause mortality, and success of TEVAR measured by complete false lumen thrombosis of the treated aortic segment were assessed and compared between patients treated with and without beta-blocker use postoperatively. Cox proportional hazards models were used to estimate the effect of beta-blocker therapy on outcomes.
Result(s): A total of 1147 patients undergoing TEVAR for TBAD were identified, with a mean follow-up of 18 +/- 12 months (median, 14 months). The mean age was 61.3 +/- 11.8 years, and 791 (71%) were men. Of the 1147 patients, 935 (84%) continued beta-blocker therapy at discharge and follow-up. Patients receiving beta-blocker therapy were more likely to have an entry tear originating in zones 1 to 2 (22% vs 13%; P =.022). The prevalence of acute, elective, and symptomatic TBAD, concurrent aneurysms, number of endografts used, distribution of the proximal and distal zones of dissection, and operative time were comparable between the two groups. At 18 months, significantly more complete false lumen thrombosis (58.4% vs 47.4%; P =.018; Fig) was observed in the patients with beta-blocker use. However, the rates of aortic-related reintervention (12.8% vs 8.8%; log-rank P =.396) and mortality (0.7% vs 0.1%; log-rank P =.401) were similar in those with and without beta-blocker therapy. Even after adjusting for clinical and operative factors, continuous postoperative beta-blocker use was associated with increased complete false lumen thrombosis (hazard ratio, 1.56; 95% confidence interval, 1.10-2.21; P =.012) but did not affect all-cause mortality or aortic-related reintervention (Table). When analyzed separately, postoperative angiotensin-converting enzyme inhibitor use did not affect the rates of aortic-related reintervention, complete false lumen thrombosis, or mortality.
Conclusion(s): Beta-blocker use was associated with the promotion of complete false lumen in patients undergoing TEVAR for TBAD. In addition to its role in acute TBAD, anti-impulse control appears to confer favorable aortic remodeling after TEVAR. Beta-blocker therapy might improve the outcomes after TEVAR for TBAD. [Formula presented] [Formula presented]
Copyright